Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 285

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Endometrial cancer

Not recruiting

Study on the Effectiveness of Biomarker Staging Compared to Conventional Staging in Women with Early-Stage Endometrial Cancer Using Paclitaxel and Carboplatin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Karolinska University Hospital

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing MK-7684A with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm malignant

Not recruiting

Study on the Long-Term Safety of Sacituzumab Govitecan for Patients with Metastatic Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Gilead Sciences Inc.

Breast cancer stage III+3

Not recruiting

Study on Preoperative Treatment for HER2 Positive Breast Cancer Using Docetaxel, Pertuzumab, and Trastuzumab in Patients with Primary Breast Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Karolinska University Hospital

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of BLU-222 Alone and with Drug Combination for Patients with Advanced Solid Tumors, Including Breast and Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Blu-222
  • Sponsor:Blueprint Medicines Corp.

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Myelodysplastic syndrome

Not recruiting

Study Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Haematological malignancy

Not recruiting

Study on the Safety and Effects of Favezelimab and Pembrolizumab for Patients with Blood Cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Malignant mast cell neoplasm

Not recruiting

Study of BMS-986449 and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bms-986449-03
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Basal cell carcinoma

Not recruiting

Study on Tirbanibulin for Treating Superficial Basal Cell Carcinoma in Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tirbanibulin
  • Sponsor:Centre Hospitalier Universitaire De Nice

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Resectable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.